PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   342 Trials   12240 News 
477 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epidaza (chidamide) / Chipscreen
ChiCTR-OPC-16008628: Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma

Recruiting
4
20
 
Chidamide with Rituximab
Qilu Hospital, Shandong University; Level of the institution:, none
Germinal center subtype of Diffuse Large B Cell Lymphoma
 
 
ChiCTR1800015871: A clinical study of chidamide with FLAG (fludarabine+cytarabine+G-CSF) in the treatment of relapsed /refractory /first cycle induced non-remission acute myeloid leukemia

Recruiting
4
10
 
Chidamide
Anhui Provincial Hospital; Anhui Provincial Hospital, chipscreen
Acute myeloid leukemia
 
 
ChiCTR-OPC-16010301: Efficacy and safety of chidamide, bortezomib and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study

Recruiting
4
80
 
bortezomib, chidamide and dexamethasone combination protocol
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Project funding
Multiple Myeloma
 
 
ChiCTR-OIC-17011303: A prospective, open-lable, single-arm, muti-center study evaluating the efficacy and saftety of chidamide in combination with CHOP in patients with newly diagnosed peripheral T-cell lymphoma (PTCL)

Recruiting
4
39
 
Chidamide+CHOP
the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, none
Peripheral T-cell lymphoma
 
 
NCT04490590: A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Recruiting
4
30
RoW
Chidamide+ Etoposide
Mingzhi Zhang
NK/T-Cell Lymphoma
10/20
10/21
ChiCTR2000037232: Azacitidine plus chidamide in patients with T/NK-cell lymphoma : a prospective, multicentre, phase 2 trial

Recruiting
4
30
 
Azacitidine plus chidamide
Anhui Provincial Cancer Hospital; Anhui Provincial Cance Hospital, Self-collected
T/NK-cell lymphoma
 
 
ChiCTR2100048016: A multicenter, prospective real-world study of chidamide combined with fulvestrant in the treatment of advanced breast cancer

Not yet recruiting
4
100
 
Chidamide plus fulvestrant
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Shenzhen Chipscreen Biosciences Co.,Ltd.
Breast cancer
 
 
NCT05191914: Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Not yet recruiting
4
20
NA
Chidamide+ Fulvestrant
Liaoning Tumor Hospital & Institute
Breast Cancer
07/22
12/22
ChiCTR2100046678: A clinical trail of chidamide plus exemestane in neoadjuvant therapy for early Hormone receptor-positive breast cancer

Recruiting
4
20
 
chidamide plus exemestane
Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Shenzhen Chipscreen Biosciences Co.,Ltd.
breast cancer
 
 
ChiCTR2100053788: A prospective, multicenter, single-arm clinical trial of chidamide in combination with exemestane in patients with hormone receptor-positive, HER2-negative advanced breast cancer

Not yet recruiting
4
20
 
chidamide in combination with exemestane
The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China
breast cancer
 
 
ChiCTR2200061380: A prospective, single-arm, multicenter clinical study of the efficacy and safety of veneclax combined with chidamide in the treatment of adult patients with high-risk myelodysplastic syndrome who have failed demethylating drugs

Not yet recruiting
4
20
 
conventional chemotherapy
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, funding
Myelodysplastic Syndrome
 
 
ChiCTR2100044282: A single-arm, single-center, observational clinical study of chidamide combined with fulvestrant in the treatment of HR+/HER2- advanced breast cancer that has failed endocrine therapy

Recruiting
4
30
 
Chidamide combined with fulvestrant
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, self-raised
Breast cancer
 
 
ChiCTR2200058721: Open-ended prospective clinical trial of skeleton scheme based on epigenetics in combination with DEL chemotherapy in relapsed/refractory children with acute T-lymphocyte leukemia (T-ALL) or T cell lymphoblastic lymphoma (T-NHL)

Not yet recruiting
4
60
 
Chidamide + HMAs + Venetoclax+Dex+VP16+Peg-Asp
Children's Hospital of Soochow University; Children's Hospital of Soochow University, Suzhou government and Children's Hospital of Soochow University
acute T-lymphocyte leukemia or T cell lymphoblastic lymphoma
 
 
ChiCTR1900025028: Chidamide for maintenance therapy of peripheral T cell lymphoma (PTCL) patients, a multi-center, prospective, randomized, open-label trial

Not yet recruiting
4
273
 
chidamide monotherapy ;N/A
Harbin Institute of Hematology & Oncology; Harbin Institute of Hematology & Oncology, Self-collected
Peripheral T cell lymphoma
 
 
ChiCTR2100049723: Efficacy of Chidamide plus BVD versus BVD in patients with relapse/refractory MM: a prospective, multicenter, randomized controlled clinical trial

Not yet recruiting
4
120
 
Chidamide plus BVD ;BVD
Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, self-funded
multiple myeloma
 
 
ChiCTR1800017698: A single arm, open label study for evaluation the effect and saft of Chidamide in the treatment of HBV positive diffuse large B cell lymphoma

Recruiting
4
20
 
maintenance of Chidamide
the First Hospital of Jilin University; The First Hospital of Jilin University, Shenzhen microbiological science and Technology Co, Ltd.
Diffuse large B cell lymphoma
 
 
ChiCTR2200060408: Maintenance therapy with Chidamide in patients with newly developed peripheral T-cell lymphoma after sequential autologous hematopoietic stem cell transplantation with Chidamide combined with BeMit chemotherapy

Not yet recruiting
4
48
 
Maintenance therapy with Chidamide and BeMit regimen after sequential autologous stem cell transplantation
Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, none
newly developed peripheral T-cell lymphoma
 
 
ChiCTR2300068673: Efficacy and safety of Zimberelimab combined with Chidamide and etoposide/gemcitabine in the treatment of peripheral T-cell lymphoma

Recruiting
4
20
 
Zimberelimab combined with Chidamide and etoposide/gemcitabine
Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet
Peripheral T-cell lymphoma
 
 
ChiCTR2300075789: Multicenter single-arm clinical study of Chidamide combined with T/TP regimen in first-line treatment of advanced triple negative breast cancer

Recruiting
4
93
 
Chidamide combined with T/TP regimen
China-Japan Friendship Hospital; China-Japan Friendship Hospital, Beijing Health Promotion Association
triple negative breast cancer
 
 
Phase II clinical study of chidamide combination regimen in second-line treatment of gastric cancer, ChiCTR2300077868: A multicenter, open-label, phase II clinical trial of chidamide combined with immunotherapy and chemotherapy as second-line treatment for advanced metastatic gastric cancer

Not yet recruiting
4
78
 
Chidamide + tislelizumab + chemotherapy; Chidamide + cardonilizumab + chemotherapy
Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University, Self-raised
advance gastric carcinoma
 
 
ChiCTR2400081280: A single arm, multicenter, exploratory clinical study of dalpiciclib combined with chidamide and letrozole in the adjuvant treatment of HR positive and HER2 negative breast cancer

Not yet recruiting
4
30
 
dalpiciclib combined with chidamide and letrozole
An Yang Tumor Hospital; An Yang Tumor Hospital, raise independently
breast cancer
 
 
ChiCTR2300075418: Clinical study of Mitoxantrone liposome, Azacitidine and Chidamide in the treatment of angioimmunoblastic T-cell lymphoma (AITL)

Recruiting
4
45
 
Mitoxantrone liposome, Azacitidine and Chidamide
Shanxi Cancer Hospital/Cancer Hospital of the Chinese Academy of Medical Sciences, Shanxi Hospital; Shanxi Cancer Hospita, Corporate Sponsorship
Angioimmunoblastic T-cell lymphoma
 
 
ChiCTR2100042420: Tucidinostat combined with AI versus AI alone for hormone receptor-positive, HER2-negative breast cancer with poor efficacy of neoadjuvant chemotherapy: a phase II, multicenter, prospective, controled study

Recruiting
4
40
 
Tucidinostat combined with AI (±OFS) ;AI alone (±OFS)
The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, self-raised
breasr cancer
 
 
ChiCTR2300075967: Clinical study of DC-Gemox regimen in relapse or refractory AITL

Recruiting
4
20
 
Duvelisib and Chidamide in combination with CHOP regimen
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded
Angioimmunoblastic T cell lymphoma
 
 
ChiCTR2300079201: Clinical study of AC-MIT regimen in new diagnosis AITL

Recruiting
4
15
 
Azacitidine and Chidamide in combination with Mitoxantrone Hydrochloride Liposome
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded
Angioimmunoblastic T cell lymphoma
 
 
ChiCTR2300075225: Safety and efficacy of Chidamide combined with chemotherapy in the treatment of newly diagnosed T-cell acute lymphoblastic leukemia in children: a multicenter randomized controlled study

Not yet recruiting
4
160
 
Dexamethasone, vincristine, daunorubicin, asparaginase; Dexamethasone, Vincristine, Daunorubicin, Asparaginase, Cedaramine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, No
Childhood T-cell acute lymphoblastic leukemia
 
 
2019-002521-30: A study in patients with skin cancer

Not yet recruiting
3
480
RoW, Europe
Tucidinostat, HBI-8000, Tablet, Concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion nivolumab
HUYABIO International, LLC, HUYABIO International
Metastatic or unresectable melanoma, Skin Cancer, Diseases [C] - Cancer [C04]
 
 
DEB, NCT04231448: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruiting
3
423
RoW
R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo
Chipscreen Biosciences, Ltd.
Diffuse Large B-cell Lymphoma
07/23
03/25
NCT05075460: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Recruiting
3
107
RoW
Tucidinostat, Azacitidine combined with CHOP
Peking Union Medical College Hospital
T-cell Lymphoma
05/24
10/24
RJ-NKTCL-3, NCT06255795: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma

Not yet recruiting
3
142
RoW
chidamide, anti-PD1 antibody, and pegaspargase, DDGP
Ruijin Hospital
Extranodal Natural Killer T Cell Lymphoma
12/26
12/28
NCT06497985: Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Not yet recruiting
3
430
NA
Tucidinostat, Chidamide, Sintilimab, Bevacizumab, Fruquintinib
Chipscreen Biosciences, Ltd.
Colorectal Cancer
05/28
09/28
NCT04674683: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Active, not recruiting
3
450
Europe, Japan, US, RoW
HBI-8000 in combination with nivolumab, For HBI-8000: tudicdinostat; For nivolumab: OPDIVO®, Placebo in combination with nivolumab, For nivolumab: OPDIVO®
HUYABIO International, LLC., Bristol-Myers Squibb
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
12/24
10/25
NCT05466318: ChiCGB vs BEAM in High-risk or R/R Lymphomas

Recruiting
3
306
RoW
Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant
Sichuan University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
12/25
12/25
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Recruiting
3
176
RoW
Experimental drug, CAP, Control Rx, FOLFIRI+BEV
Sun Yat-sen University
Metastatic Microsatellite-stable Colorectal Cancer
01/26
01/27
NCT05931263: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Recruiting
3
104
RoW
C-BEAM Regimen, BEAM Regimen
The First Affiliated Hospital with Nanjing Medical University
Newly Diagnosed Peripheral T-cell Lymphoma
02/26
02/28
NCT06122389: SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Recruiting
3
130
RoW
SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
Jiangsu HengRui Medicine Co., Ltd.
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
05/26
07/26
NCT05678933: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Enrolling by invitation
3
200
RoW
Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone
Tianjin Medical University Cancer Institute and Hospital
Peripheral T-cell Lymphoma Targeted Therapy
12/27
12/29
NCT04668690: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Not yet recruiting
3
190
RoW
Mitoxantrone Hydrochloride Liposome Injection, HE071, Liposomal Mitoxantrone Hydrochloride Injection, Chidamide
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Peripheral T Cell Lymphoma
12/27
12/28
NCT05253066: Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Not yet recruiting
2/3
130
NA
Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Shengjing Hospital
Breast Neoplasms
07/22
01/25
PDT-Ph-Like, NCT03564470: Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Recruiting
2/3
120
RoW
Chidamide, HDACi chidamide, Dasatinib, TKI dasatinib
Nanfang Hospital of Southern Medical University
Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
08/23
08/23
ChiCTR-TNC-10000811: Phase II Clinical Trial of Chidamide in Patients with Peripheral T-cell Lymphoma

Recruiting
2
51
 
口服西达本胺每周两次,每次30mg
Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences, Ltd, Chipscreen Biosciences,Ltd.
Peripheral T-cell Lymphoma
 
 
ChiCTR-TNC-10000806: Study of Chidamide in Patients With Cutaneous T-cell Lymphoma

Completed
2
82
 
Oral Chidamide 30mg twice weekly
Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences Co., Ltd., Chipscreen Biosciences Co., Ltd.
Cutaneous T-cell lymphoma
 
 
ChiCTR-IIC-15006786: The combined regimen of Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate for Relapsed/ Refractory Peripheral T Cell Lymphoma (PTCL), a multicenter, single arm, open-label phase II clinical trial

Recruiting
2
92
 
Chidamide with Prednisone, Cyclophosphamide, Etoposide, and Methotrexate
Sun Yat-sen University Cancer Center; Level of the institution:, Uncertain at present
Peripheral T Cell Lymphoma
 
 
ChiCTR-IIR-15007350: Radomized and Controlled Phase II Study and Prognosis Analysis for the Early Stage and High Risk Extranodal Nasal NK/T Cell Lymphoma

Recruiting
2
98
 
Chidamide+radiotherapy+chemotherapy ;radiotherapy+chemotherapy
Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing Marathon of Hope Special Found from Cancer Foundation of China
Extranodal nasal NK/T cell lymphoma
 
 
ChiCTR1800015471: Phase II clinical study of chidamide monotherapy in the treatment of relapsed or refractory extranodal nasal type NK/T cell lymphoma

Not yet recruiting
2
80
 
Chidamide
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Shenzhen Chipscreen Biosciences, Ltd; West China Hospital of Sichuan University
NK/T lymphoma
 
 
ChiCTR1800017740: A prospective, single-arm evaluating the efficacy and safety of chidamide, CAG and DLI in patients with high risk or relapse hematological malignancies after allogeneic stem cell transplantation

Recruiting
2
30
 
chidamide+CAG+DLI
Chinese People's Liberation Army General Hospital; China PLA General Hospital, patients
acute leukemia or myelodysplastic syndrome
 
 
NCT03617432: Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Recruiting
2
114
RoW
Chidamide, epidaza, Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone
Peking University, Peking University International Hospital, Shandong Tumor Hospital, Jiangxi Provincial Cancer Hospital
Experimental Tumor
09/20
09/22
ChiCTR1800015332: Study of Chidamide combined decitabine and etoposide in treating refractory and relapsed adult AML

Recruiting
2
84
 
CDE regimen
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Chipscreen (Chidamide)
Acute myeloid leukemia
 
 
NCT03611231: Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Not yet recruiting
2
43
RoW
Chidamide, epidaza
Peking University, Hebei Medical University Fourth Hospital, Peking University International Hospital
Experimental Tumor
12/20
12/22
NCT03853044: Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Active, not recruiting
2
23
RoW
Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Ruijin Hospital
Angioimmunoblastic T-cell Lymphoma
06/21
12/22
NCT04025593: Biomarker Guided Treatment in DLBCL

Recruiting
2
128
RoW
Cyclophosphamide, Rituximab, Doxorubicin, Vincristine, Prednisone, Ibrutinib, Lenalidomide, chidamide, decitabine
Ruijin Hospital
Diffuse Large B Cell Lymphoma
07/21
06/23
C-R-HDMTX, NCT04516655: A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients

Not yet recruiting
2
51
NA
chidamide combined with rituximab and high-dose methotrexate
Fudan University
Central Nervous System Lymphoma
09/21
08/23
ChiCTR1900027562: Clinical study for chidamide combined with bortezomib, dexamethasone and doxorubicin hydrochloride liposome injection in the treatment of relapse/refractory multiple myeloma

Recruiting
2
15
 
Refractory/relapsed multiple myeloma patient group
Peking University People's Hospital; Peking University People's Hospital, Self preparation
Multiple myeloma
 
 
NCT03245905: Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Recruiting
2
100
RoW
Chidamide, epidaza
Sun Yat-sen University
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
12/21
12/21
NCT03629873: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

Active, not recruiting
2
69
RoW
Chidamide, Carmustine, Etoposide, Cytarabine, Cyclophosphamide, Autologous hematopoeitic stem cell transplantation
The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma, Double-hit Lymphoma
12/21
12/21
ChiCTR2100050169: Chidamide combined with rituximab in the treatment of recurrent / refractory elderly (over 65 years old) diffuse large B-cell lymphoma: a phase II clinical study

Recruiting
2
30
 
Chidamide combined with rituximab
Tianjin Union Medical Center; Tianjin Union Medical Center, self-financing
lymphoma
 
 
NCT04329130: Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting
2
44
RoW
Chidamide, Lenalidomide
Sun Yat-sen University
Relapsed or Refractory Peripheral T-cell Lymphoma
03/22
03/25
AITL, NCT04319601: Rituximab Combined With Chidamide and Lenalidomide for r/r

Recruiting
2
26
RoW
Rituximab, chidamide, lenalidomde
Zhejiang Cancer Hospital
Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
03/22
12/22
ChiCTR2000041542: Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer

Recruiting
2
76
China
Chidamide+Tislelizumab(±chemotherapy)
The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project
Non-small cell lung cancer
 
 
ChiCTR2000041541: Phase II study of Chidamide and Tislelizumab in advanced Urothelial carcinoma

Recruiting
2
20
China
Chidamide plus Tislelizumab and chemotherapy
The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project
Urothelial carcinoma
 
 
NCT04831710: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Not yet recruiting
2
83
RoW
Sintilimab, Tyvyt®, Chidamide, Epidaza
Sun Yat-sen University
Angioimmunoblastic T-cell Lymphoma
04/22
04/23
NCT04192903: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Recruiting
2
55
RoW
Chidamide combined with Cisplatin
Fudan University
Triple-negative Breast Cancer
06/22
06/22
NCT05088226: Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Recruiting
2
50
RoW
Ruxolitinib combined with Chidamide., Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
Chinese PLA General Hospital
Peripheral Blood Stem Cell Transplantation
06/22
06/23
RJ-PTCL-2, NCT04480125: Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Recruiting
2
28
RoW
Azacitidine, Chidamide
Ruijin Hospital
Peripheral T-cell Lymphoma
06/22
06/24
NCT04414969: Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Recruiting
2
35
RoW
Anti-PD-1 antibody+Peg-Asparaginase+Chidamide, Anti-PD-1 antibody;Peg-Asparaginase;Chidamide
Hunan Cancer Hospital
Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity
07/22
07/25
NCT04724239: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Active, not recruiting
2
48
RoW
Sintilimab, Chidamide, IBI305, Bevacizumab
Sun Yat-sen University
Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
07/22
12/23
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Recruiting
2
200
RoW
Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab
Chinese PLA General Hospital
Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant
08/22
08/25
NCT04562311: Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
43
RoW
Chidamide with tislelizumab
Sun Yat-sen University
Bladder Cancer Stage IV
09/22
09/23
NCT05076786: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Recruiting
2
28
RoW
Chidamide, Epidaza, Etoposide + Cisplatin/Carboplatin, EP/EC regimen
Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University
Neuroendocrine Tumors, Neuroendocrine Carcinoma
10/22
10/24
ChiCTR2000039464: Tlislelizumab Plus Chidamide as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)

Recruiting
2
25
China
Tislelizumab + Chidamide
Chinese PLA General Hospital ; Chinese PLA General Hospital, Beigene.co.,ltd + chipscreen
Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)
 
 
NCT05113355: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Recruiting
2
23
RoW
Chidamide, Epidaza, Sintilimab, Tyvyt
Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm
11/22
11/24
NCT04022005: Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Completed
2
54
RoW
Chidamide, Rituximab, Gemcitabine,Oxaliplatin
Sun Yat-sen University
Lymphoma, Large B-Cell, Diffuse
11/22
03/23
NCT04661943: Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Recruiting
2
20
RoW
Tucidinostat, Chidamide,CS055,HBI-8000
oubai
Diffuse Large B-cell Lymphoma
11/22
11/22
NCT05008666: Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Not yet recruiting
2
37
RoW
Sintilimab, Chidamide, Azacitidine, L-DEP
Sun Yat-sen University
Safety and Efficacy
11/22
04/23
NCT04296786: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Recruiting
2
52
RoW
Sintilimab, Chidamide
Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Longfu Hospital, Dongzhimen Hospital, Beijing
Cutaneous T-cell Lymphoma
12/22
12/24
PCR, NCT05115409: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL

Not yet recruiting
2
27
NA
Anti-PD-1 Antibody Plus Chidamide and Rituximab
Sun Yat-sen University, Chipscreen Biosciences, Ltd.
Relapsed or Refractory DLBCL
12/22
12/24
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
NCT04984018: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Not yet recruiting
2
73
NA
chidamide + camrelizumab
The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
12/22
12/23
NCT05056974: A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Completed
2
11
RoW
UB-421, chidamide
United BioPharma
HIV-1 Infection
02/23
02/23
NCT05400993: Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Recruiting
2
59
RoW
Chidamide, pharmorubicin, Cyclophosphamide, Docetaxel
Shengjing Hospital
Breast Cancer
05/23
05/24
ChiCTR2200061074: A multicenter, single-arm, prospective, phase II clinical study of Chidamide combined with chemotherapy in neoadjuvant therapy for HR-positive/HER2-negative breast cancer

Not yet recruiting
2
59
 
Chidamide+pharmorubicin +cyclophosphamide+docetaxel neoadjuvant therapy
Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, Shenzhen Chipscreen Biosciences Co.,Ltd.
Breast cancer
 
 
NCT05330364: Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Recruiting
2
31
RoW
Chidamide, Cladribine
Ge Zheng
Acute Myeloid Leukemia
06/23
06/23
NCT05129189: Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Recruiting
2
15
RoW
ASC22 group
Shanghai Public Health Clinical Center
HIV Infections
07/23
07/23
ChiCTR2000037642: A non-randomized controlled, multicenter phase II clinical trial to evaluate the efficacy and safety of Chidamide combined with Fulvestrant+ /-Sintinlimab treatment of recurrent / metastatic breast cancer patients with HR positive and HER-2 negative breast cancer

Recruiting
2
90
 
Chidamide+Fulvestrant+Sintinlimab ;Chidamide+Fulvestrant ;Fulvestrant
Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute, INNOVENT
Breast cancer
 
 
NCT05749575: Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Recruiting
2
28
RoW
Chidamide Plus Toripalimab Plus Paclitaxel
Sun Yat-sen University
Breast Cancer
08/23
08/24
NCT05495100: A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

Recruiting
2
45
RoW
Mitoxantrone liposome、Chidamide、Azacitidine
Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo No. 1 Hospital, Jinhua Central Hospital, Huizhou Municipal Central Hospital
Peripheral T Cell Lymphoma
08/23
08/24
NCT04994210: Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Recruiting
2
30
RoW
Sintilimab, Tyvyt®, Chidamide, Epidaza
Sun Yat-sen University
Safety and Efficacy
08/23
08/25
NCT05808582: Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Not yet recruiting
2
60
NA
chidamide,fulvestrant, Regular Visits
The First Affiliated Hospital with Nanjing Medical University
Hormone Receptor-positive Advanced Breast Cancer
09/23
09/24
ChiCTR2000034888: Chidamide combined with sintilimab for advanced and refactory non-small cell lung cancer: a prospective,multi-cohort, phase Ib/II clinical study

Not yet recruiting
2
60
 
Chidamide combined with sintilimab ;Chidamide combined with sintilimab ;Chidamide combined with sintilimab
National Cancer Center / National Cancer Clinical Medicine Research Center / Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences; National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, None
Non-small Cell Lung Cancer
 
 
NeoTEE, NCT04465097: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed
2
30
RoW
Tucidinostat, Chidamide, Epidaza, Exemestane, Ovarian function suppression
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
10/23
10/23
NCT05519865: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Active, not recruiting
2
118
RoW
Tucidinostat, Chidamide, CS055, Tislelizumab
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
10/24
10/24
NCT05411874: A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP

Not yet recruiting
2
100
NA
Chidamide, HD-DXM
Shandong University
Thrombocytopenia
10/23
10/24
NCT05085626: Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Recruiting
2
40
RoW
fluzoparib+chidamide, fluzoparib+camrelizumab
Tianjin Medical University Cancer Institute and Hospital
Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
10/23
12/24
NCT05438706: A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Not yet recruiting
2
70
RoW
chidamide, camrelizumab, carboplatin, capecitabine
Fudan University
Triple-negative Breast Cancer
11/23
07/24
NCT06151106: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Recruiting
2
33
RoW
Chidamide combined with Duvillisib
The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
12/24
12/25
NCT06158386: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Recruiting
2
33
RoW
Chidamide combined with Linperlisib
The First Affiliated Hospital of Xiamen University, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital
Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
12/24
12/25
Sincerely20, NCT04512534: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Recruiting
2
51
RoW
PD-1 antibody+ HDAC inhibitor, Sintilimab, Chidamide
Fudan University
Peripheral T-cell Lymphoma
12/23
09/25
NCT04999540: Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Not yet recruiting
2
73
NA
Tucidinostat, Fulvestrant
Guangdong Women and Children Hospital
Breast Cancer
12/23
12/24
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed
2
34
RoW
Chidamide, CS055, Envafolimab, KN035
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
02/23
05/24
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Recruiting
2
87
RoW
Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001
Ruihua Xu
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
12/23
12/25
 

Download Options